The Role of Levator Ani Muscle Reconstruction Technology in Urinary Incontinence Recovery
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Aug 6, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special procedure called Levator Ani Muscle Reconstruction can help men recover their ability to control urination after surgery for prostate cancer. The trial involves patients who are having a specific type of surgery called robot-assisted laparoscopic radical prostatectomy (RARP) for prostate cancer. Participants in the study are randomly assigned to one of three groups: some will receive the lateral reconstruction, others will get the posterior reconstruction, and a third group will not have any reconstruction. The researchers will track how well these methods help improve urinary control and overall quality of life for patients.
To join the trial, participants need to be men aged between 65 and 74 who have been diagnosed with prostate cancer but have not had any prior surgery for it. They should also be suitable candidates for the RARP surgery. Throughout the study, participants will have regular check-ups to share information about their urinary function, including how many pads they use daily and how much urine they leak in a day. This trial aims to find the best approach to help men regain control over their urinary function after surgery, ultimately improving their quality of life.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with prostate cancer and preoperative clinical stage of cT2\~T3aN0M0
- • Complies with the indications for RARP surgery
- Exclusion Criteria:
- • History of urinary incontinence or urethral stricture
- • Previous prostate related surgical treatment
- • Contraindications for RARP surgery
- • The patient or their family members refuse to participate
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Kan Gong
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported